Hansoh Pharma (03692): The application for the marketing authorization of HS-10365 capsules has been accepted by the National Medical Products Administration.
Hanson Pharmaceuticals (03692) announced on October 23, 2025 that the group has successfully developed a highly selective transfection reagent for innovative drugs...
Hansoh Pharma (03692) announced that on October 23, 2025, the group's new drug, a highly selective transduction rearrangement inhibitor capsule HS-10365, has received acceptance for market approval application (NDA) from the National Medical Products Administration (NMPA) of China. This drug is intended for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with RET gene fusion positivity.
Related Articles
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
